Rrp Semiconductor Limited (BOM:504346)

Intra-Cellular Therapies Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Operating Revenue	315.91	3.8	-	-	-
Other Revenue	3.6	-	-	-	-
Revenue	319.51	3.8	-	-	-
Revenue Growth (YoY)	8308.24%	-	-	-	-
Cost of Revenue	194.68	1.85	-	-	-
Gross Profit	124.83	1.95	-	-	-
Selling, General & Admin	2.08	0.24	0.24	0.23	0.23
Other Operating Expenses	5.22	0.62	0.48	0.43	0.59
Operating Expenses	7.3	0.86	0.72	0.66	0.82
Operating Income	117.53	1.09	-0.72	-0.66	-0.82
Interest Expense	-2.27	-1.26	-	-	-0
Other Non Operating Income (Expenses)	-0.62	-	0	-0	-
EBT Excluding Unusual Items	114.64	-0.17	-0.72	-0.66	-0.83
Pretax Income	114.64	-0.17	-0.72	-0.66	-0.83
Income Tax Expense	30	-	-	-	-
Net Income	84.64	-0.17	-0.72	-0.66	-0.83
Net Income to Common	84.64	-0.17	-0.72	-0.66	-0.83
Shares Outstanding (Basic)	14	0	0	0	0
Shares Outstanding (Diluted)	14	0	0	0	0
Shares Change (YoY)	14029.72%	-	-	-	-
EPS (Basic)	5.99	-1.70	-7.22	-6.57	-8.25
EPS (Diluted)	5.99	-1.70	-7.22	-6.57	-8.25
Gross Margin	39.07%	51.32%	-	-	-
Operating Margin	36.78%	28.74%	-	-	-
Profit Margin	26.49%	-4.47%	-	-	-
EBIT	117.53	1.09	-0.72	-0.66	-0.82
EBIT Margin	36.78%	28.74%	-	-	-
Effective Tax Rate	26.17%	-	-	-	-
Revenue as Reported	319.51	3.8	-	-	-

Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.